Onco Wiki / Maladie

Carcinome de la glande salivaire

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

IDDIS-SALIVARY
TypeMaladie
Alias
Carcinome kystique adénoïdienMASC (carcinome sécréteur analogue mammaire)Carcinome du canal salivaireCancer de la glande salivaireКарцинома слинних залоз
Étatreviewed 2026-04-27 | pending_clinical_signoff
MaladiesAucune déclaration
SourcesSRC-NCCN-NSCLC-2025

Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.

Source YAML

icd_o_3_morphology8500/3
icd_o_3_topography["C07", "C08"]
icd_10C07, C08
who_classificationWHO Head and Neck Tumours 5th ed (2024): Salivary gland tumours (>25 distinct histologic entities)

Capacités

Notes

Umbrella disease; therapy is HISTOLOGY-driven. Two histologies are highly actionable: - Mammary analogue secretory carcinoma (MASC, parotid most common): near-100% ETV6-NTRK3 fusion (or NTRK1/2 partner variants); larotrectinib / entrectinib transformative in advanced disease (FDA tumor-agnostic). - Salivary duct carcinoma (SDC): aggressive, often parotid; molecular profile mimics breast / prostate: * AR-positive (~70-80%): bicalutamide + LHRH agonist (EORTC-1206); active even without prior antiandrogen exposure. * HER2-amplified (~30-40%): trastuzumab + docetaxel (Takahashi et al, JCO 2019); trastuzumab deruxtecan in DESTINY-PanTumor02; zanidatamab. * HRAS mutant (~10-15%): tipifarnib (KO-TIP-007). * PIK3CA / PI3K pathway: alpelisib + tipifarnib in KURRENT-HN. - Adenoid cystic carcinoma (ACC): MYB-NFIB fusion ~60% (not currently drugged); NOTCH1 mutation ~15% (gamma-secretase inhibitors — AL101 / ACCURACY trial). Indolent course with late distant relapses (lung most common). Chemotherapy generally low-yield; multikinase TKIs (lenvatinib) modest activity. - Mucoepidermoid carcinoma: CRTC1-MAML2 fusion ~50% (prognostic, not therapeutic). Surgery + adjuvant RT for high-grade.

Utilisé par

Pertinence thérapeutique

Algorithmes

Indication

Questionnaires

Signal d’alerte

Évaluateurs